Matthew Angel
Chief Executive Officer en Factor Bioscience, Inc. .
Fortuna: 418 757 $ al 31/03/2024
Cargos activos de Matthew Angel
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Factor Bioscience, Inc.
Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01/01/2011 | - |
Chairman | 01/01/2011 | - | |
Founder | 01/01/2011 | - | |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The private company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Director/Board Member | 01/01/2020 | - |
Chief Tech/Sci/R&D Officer | - | - | |
Founder | 01/01/2020 | - | |
Corporate Secretary | - | - | |
Treasurer | - | - |
Historial de carrera de Matthew Angel
Antiguos cargos conocidos de Matthew Angel.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
ETERNA THERAPEUTICS INC. | Chief Executive Officer | 09/08/2023 | 31/12/2023 |
President | 09/08/2023 | 31/12/2023 | |
ETERNA THERAPEUTICS INC. | Director/Board Member | 07/06/2022 | 04/08/2023 |
Chief Executive Officer | 26/05/2022 | 04/08/2023 | |
Corporate Officer/Principal | - | 26/05/2022 | |
President | 26/05/2022 | 04/08/2023 | |
Novellus LLC
Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Director/Board Member | 01/01/2014 | - |
Founder | 01/01/2014 | 01/07/2021 | |
Corporate Secretary | 01/01/2014 | 01/07/2021 |
Formación de Matthew Angel.
Massachusetts Institute of Technology | Doctorate Degree |
Princeton University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Operativa
Director/Board Member | 3 |
Founder | 3 |
Chief Executive Officer | 3 |
Sectorial
Health Technology | 3 |
Finance | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ETERNA THERAPEUTICS INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Novellus LLC
Novellus LLC Pharmaceuticals: MajorHealth Technology Novellus LLC operates as a pharmaceutical company. The company is headquartered in Cambridge, MA. | Health Technology |
Factor Bioscience, Inc.
Factor Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Factor Bioscience, Inc. develops regenerative medicine by targeting and repairing the molecular origins of disease. It offers gene editing, cell reprogramming and nucleic-acid delivery. The company was founded by Matt Angel and Christopher Rohde in 2011 and is headquartered in Cambridge, MA. | Commercial Services |
Exacis Biotherapeutics, Inc.
Exacis Biotherapeutics, Inc. Medical/Nursing ServicesHealth Services Part of Eterna Therapeutics, Inc., Exacis Biotherapeutics, Inc. is a development stage immuno-oncology company based in Cambridge, MA. Exacis uses its proprietary-based technologies to engineer next generation off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all development and commercial rights for these investigational candidates. Exacis' approach avoids the use of DNA and viruses and instead uses a proprietary-based technology to generate iPSCs and to edit their genome to create stealthed, performance-enhanced allogeneic NK and T cell products, termed ExANK™, Exacar-NK™, and Exacar-T™ cells. The private company was founded in 2020 by Gregory Fiore, Matthew Angel, James Pan. Gregory Fiore has been the CEO since 2020. Exacis Biotherapeutics was acquired by Eterna Therapeutics, Inc. on May 02, 2023 for $49 million. | Health Services |
- Bolsa de valores
- Insiders
- Matthew Angel
- Experiencia